Cargando…

Clinical significance in the number of involved lymph nodes in patients that underwent surgery for pathological stage III-N2 non-small cell lung cancer

PURPOSE: This study investigated whether the number of involved lymph nodes is associated with the prognosis in patients that underwent surgery for pathological stage (p-stage) III/N2 NSCLC. SUBJECTS: This study evaluated 121 patients with p-stage III/N2 NSCLC. RESULTS: The histological types includ...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanagiri, Takeshi, Takenaka, Masaru, Oka, Soich, Shigematsu, Yoshiki, Nagata, Yoshika, Shimokawa, Hidehiko, Uramoto, Hidetaka, Tanaka, Fumihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3212931/
https://www.ncbi.nlm.nih.gov/pubmed/22027105
http://dx.doi.org/10.1186/1749-8090-6-144
Descripción
Sumario:PURPOSE: This study investigated whether the number of involved lymph nodes is associated with the prognosis in patients that underwent surgery for pathological stage (p-stage) III/N2 NSCLC. SUBJECTS: This study evaluated 121 patients with p-stage III/N2 NSCLC. RESULTS: The histological types included 65 adenocarcinomas, 39 squamous cell carcinomas and 17 others. The average number of dissected lymph nodes was 23.8 (range: 6-55). The average number of involved lymph nodes was 5.9 (range: 1-23). The 5-year survival rate of the patients was 51.0% for single lymph node positive, 58.9% for 2 lymph nodes positive, 34.2% for 3 lymph nodes positive, and 30.0% for 4 lymph nodes positive, and 20.4% for more than 5 lymph nodes positive. The patients with either single or 2 lymph nodes positive had a significantly more favorable prognosis than the patients with more than 5 lymph nodes positive. A multivariate analysis revealed that the number of involved lymph nodes was a significant independent prognostic factor. CONCLUSION: Surgery appears to be preferable as a one arm of multimodality therapy in p-stage III/N2 patients with single or 2 involved lymph nodes. The optimal incorporation of surgery into the multimodality approach therefore requires further clinical investigation.